<?xml version="1.0" encoding="UTF-8"?>
<ref id="B77-ijms-21-03544">
 <label>77.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Giovannoni</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Hawkes</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Lechner-Scott</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Levy</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Waubant</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Gold</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>The COVID-19 pandemic and the use of MS disease-modifying therapies</article-title>
  <source>Mult. Scler. Relat. Disord.</source>
  <year>2020</year>
  <volume>39</volume>
  <fpage>102073</fpage>
  <pub-id pub-id-type="doi">10.1016/j.msard.2020.102073</pub-id>
  <pub-id pub-id-type="pmid">32334820</pub-id>
 </element-citation>
</ref>
